Development of WVE-004 to cease after Phase 1/2 trial failure

Development of WVE-004 to cease after Phase 1/2 trial failure

WVE-004, Wave Life Sciences‘ investigational treatment for amyotrophic lateral sclerosis (ALS), significantly reduces toxic proteins associated with C9orf72 genetic mutations, but that doesn’t seem to translate into functional status gains in patients. Based on findings from the Phase 1b/2a FOCUS-C9 trial (NCT04931862), the company has decided to discontinue developing…

Some sporadic ALS patients have mutation causing other diseases

A sizable portion of people with sporadic amyotrophic lateral sclerosis (ALS) carry a genetic mutation known to cause other neurological disorders, a new study shows. “This suggests shared risk factors among these diseases, shared mechanisms that cause nerves to die – and perhaps shared therapeutic strategies in the future,”…

Why last week was special in the ALS community

I love inspirational quotes and sayings. Throughout my life, I’ve stumbled upon passages from books or snippets of speeches from public figures and recognized them as a helpful way for me to understand or think about a current challenge in life. In some cases, they’ve served as mantras — easy…

To families affected by ALS, Hope Loves Company offers hope, support

Jodi O’Donnell-Ames founded Hope Loves Company after losing her husband to ALS. (Courtesy of Jodi O’Donnell-Ames) This is Jodi O’Donnell-Ames’ story: The term amyotrophic lateral sclerosis (ALS) was not a part of my vocabulary until May 1995. That’s when my husband, Kevin O’Donnell, was diagnosed with…